PubMed Health⌕ Search

PubMed · 8337853

Graves' ophthalmopathy.

Abstract

Ophthalmopathy develops in about 30% of patients who have Graves' disease. The pathogenesis, like that of the hyperthyroidism, is probably autoimmune in nature. The eye manifestations are diverse and include lid lag, soft tissue swelling, proptosis, corneal damage, diplopia, and optic neuropathy. The natural history is benign in 90% of patients, with gradual improvement over time. Therapeutic options include corticosteroid therapy, radiation, and surgical treatment. The last is usually the therapy of choice for severe or disfiguring ophthalmopathy.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

W E Barrie. 1993. Graves' ophthalmopathy.. https://pubmed.ncbi.nlm.nih.gov/8337853/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Uses and complications of mitomycin C in ophthalmology.

Mitomycin C is a chemotherapeutic agent that acts by inhibiting DNA synthesis. Its use and application in ophthalmology has been increasing in recent years because of its modulatory effects on wound healing. Current applications include pterygium surgery, glaucoma surgery, corneal refractive surgery, cicatricial eye disease, conjunctival neoplasia and allergic eye disease. Although it has been used successfully in these conditions, it has also been associated with significant complications. This article reviews the current trends and uses of mitomycin C in the eye and its reported complications.

Eye Diseases↗